International Circulation: Professor Schiffrin， thanks for speaking with us today.  As President of the ISH what do you hope will come from this conference?

 

　　Professor Schiffrin: Well my hope is always that people will interact with each other， learn， so there is learning on the part of practitioners， new approaches that will help increase the control of blood pressure and therefore improve outcomes and reduce heart attacks， strokes， renal failure， and peripheral vascular disease， heart failure， and all the consequences of hypertension on the one hand.  On the other hand， my hope is that there will be new collaborations that will somehow enhance the ability of individual researchers to carry out their research and advance our science in the field of hypertension and in general across the field of cardiovascular disease such that we may develop new treatments which will again improve outcomes.  I think that at every one of these meetings， every 2 years， there is progress and these meetings generate an enthusiasm in individuals that results in better research and accordingly better outcomes for our patients.

 

　　《国际循环》：Schiffrin教授，感谢您今天接受我们的采访。作为ISH主席，您对这次大会有着怎样的期望？

 

　　Schiffrin教授：我希望人们能够互相交流、学习。大会涉及很多能够改善血压控制进而改善患者临床结局、减少心脏病、卒中、肾衰竭、外周血管疾病、心力衰竭及其他高血压结局的实践内容和新方法。另一方面，我希望能有新的合作在一定程度上鼓励研究人员积极开展研究、促进高血压领域的学科进步。在心血管疾病领域我们还是可以研发新的治疗方法来改善患者的结局。我认为，在每个类似的会议上，每两年就会有很多新进展，这些会议能够激发医生及研究者的积极性，从而促进我们开展更好的研究并使患者得到更好的结局。

 

　　International Circulation : Are there any particular highlights this year or directions you find particularly important?

 

　　Professor Schiffrin : Well I think there are a couple of things where it was important for people to discuss about renal denervation in view of the failure of the American study and to see that there are other possibilities， new techniques， certain parameters that are critical that may not have been achieved， in fact in the American trial some parameters were achieved and they were successful where in other places it was less successful.  That discussion was very important in order for the field to advance further.  Another area is the very important aspect of atrial fibrillation， a very frequent occurrence in hypertensive patients.  I often detect atrial fibrillation in my office when I am examining a patient， de novo atrial fibrillation， and we know that we can do a lot to avoid the strokes that result from atrial fibrillation and therefore the new anticoagulants or the discussion about the new anticoagulants， there was a lot of that， and as well there was a lot about management of hypertension but as well about basic mechanisms. I think the more we discuss basic mechanisms the more we will learn about new targets and again we will be able to advance further and improve the control of hypertension which today is quite dismal in most of the world.